Q4 2022 G1 Therapeutics Inc Earnings Call Transcript
Good day, and welcome to the G1 Therapeutics Fourth Quarter Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Communications, Will Roberts.
Thank you, Andrew. Good morning, everyone, and welcome to the G1 conference call to discuss our fourth quarter and full year 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our corporate website, g1therapeutics.com.
On this morning's call, the team will provide a business overview of the fourth quarter of 2022, including an update on our clinical programs and our commercial progress in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients who were administered prior to a platinum/etoposide-containing regimen
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |